BioCentury | Jan 10, 2011
Company News

Vivalis, sanofi-aventis deal

...see BioCentury, June 14, 2010). Humalex, which Vivalis gained through its January 2010 acquisition of Humalys S.A.S....
BioCentury | Jul 12, 2010
Strategy

Building a mAb Platform

...its EB66 cell line for production of vaccines and protein therapeutics. The company's acquisition of Humalys S.A.S....
...by the scientific founders of Humalys, which was established in 2007. In January, Vivalis acquired Humalys...
...which was established in 2007. In January, Vivalis acquired Humalys for €10.4 million ($12.6 million). Humalys...
BioCentury | Jun 14, 2010
Company News

Vivalis, sanofi-aventis deal

...milestones for each indication, plus royalties. Humalex, which Vivalis gained through its January acquisition of Humalys...
BioCentury | Jun 8, 2010
Company News

Vivalis, Sanofi Pasteur in infectious mAb deal

...each indication, plus royalties. The Humalex platform, which Vivalis gained through its January acquisition of Humalys...
BioCentury | Jan 18, 2010
Company News

Humalys SAS, Vivalis deal

...Vivalis acquired antibody company Humalys for €10.4 million ($15.1 million) in cash. Humalys' Humalex technology uses...
...uses human B lymphocytes isolated directly from selected donors to identify and generate human mAbs. Humalys...
...eligible for up to €15 million ($21.8 million) over 15 years for third-party licensing payments. Humalys...
Items per page:
1 - 5 of 5
BioCentury | Jan 10, 2011
Company News

Vivalis, sanofi-aventis deal

...see BioCentury, June 14, 2010). Humalex, which Vivalis gained through its January 2010 acquisition of Humalys S.A.S....
BioCentury | Jul 12, 2010
Strategy

Building a mAb Platform

...its EB66 cell line for production of vaccines and protein therapeutics. The company's acquisition of Humalys S.A.S....
...by the scientific founders of Humalys, which was established in 2007. In January, Vivalis acquired Humalys...
...which was established in 2007. In January, Vivalis acquired Humalys for €10.4 million ($12.6 million). Humalys...
BioCentury | Jun 14, 2010
Company News

Vivalis, sanofi-aventis deal

...milestones for each indication, plus royalties. Humalex, which Vivalis gained through its January acquisition of Humalys...
BioCentury | Jun 8, 2010
Company News

Vivalis, Sanofi Pasteur in infectious mAb deal

...each indication, plus royalties. The Humalex platform, which Vivalis gained through its January acquisition of Humalys...
BioCentury | Jan 18, 2010
Company News

Humalys SAS, Vivalis deal

...Vivalis acquired antibody company Humalys for €10.4 million ($15.1 million) in cash. Humalys' Humalex technology uses...
...uses human B lymphocytes isolated directly from selected donors to identify and generate human mAbs. Humalys...
...eligible for up to €15 million ($21.8 million) over 15 years for third-party licensing payments. Humalys...
Items per page:
1 - 5 of 5